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Abstract
Background: Antiretroviral therapy (ART) has dramatically reduced morbidity and mortality among people with HIV
infection; however, mortality after the start of ART is high in resource-limited settings. We investigated risk factors
for mortality among adults starting ART in a multi-clinic community programme in South Africa.
Methods: Cohort of adults starting ART at 27 clinics between February 2005 and June 2006, followed to 31
st
March 2007. Kaplan-Meier survival estimates were used to describe overall mortality. Shared frailty Cox regression
was used to identify baseline risk factors for early mortality.
Results: Among 1350 participants (median age 35.5 years, 60% female, median CD4 count 83/μL [interquartile
range (27 - 147)], median follow-up 13.4 months), there were 185 deaths, overall mortality rate 13/100 pyrs; for 0-3,
3-9 and >9 months from ART start mortality rates were 24, 13 and 6/100 pyrs respectively. 43% of the deaths were
in the first 3 months of treatment. Risk factors for mortality in univariable analysis were baseline CD4 count, viral
load, haemoglobin and body mass index, in multivariable analysis adjusting for age and gender, only CD4 count
and haemoglobin remained independently associated with proportional hazards not being satisfied for
haemoglobin. Adjusted hazard ratios (aHR) for participants with haemoglobin <8, 8.1-9.9, >11.9(f)/12.9 (m) g/mL
were 4.99, 3.05 and 0.12 respectively comparing to 10-11.9 (f)/12.9 (m)g/mL in the first 3 months of ART. aHRs for
CD4 counts were 0.40, 0.38 and 0.34 for 50-99, 100-200 and >200/μL comparing to <50/μL.
Conclusions: The high mortality rate in the first 3 months underlines the need for earlier HIV diagnosis so that
ART can be initiated earlier. Low haemoglobin and low CD4 count are both strong predictors of mortality, and
could be used to identify individuals at high risk who might benefit from intensive case management.
Background
South Africa is estimated to have 5.7 million HIV-posi-
tive individuals out of a total population of 48.6 million
[1] and has more people living with HIV/AIDS than any
other country worldwide [2] which is a considerable
challenge for health care systems and communities
across the country. A key component of a suitable and
extensive response to this growing epidemic, especially
in communities most affected by HIV, is combination
antiretroviral therapy (cART) [3] and it is estimated that
889,000 adults (less than 49 years old) and children in
South Africa are in urgent need of this treatment [4].
Although treatment programmes have been scaled up
and increased in number they still face challenges. Stu-
dies in Sub-Saharan Africa show that one of these chal-
lenges is that mortality in these programmes is much
h i g h e ri nt h ef i r s tt h r e em o n t h s[ 5 - 9 ] .O n eo ft h er e a -
sons for this is that despite better availability of ART,
people are still diagnosed late and thus start ART when
they already have late stage disease[9]. Identifying those
at highest of early mortality risk could help target inter-
ventions to improve survival.
T h ed a t af o rt h i ss t u d yw e r ec o l l e c t e df r o mal a r g e
community based programme set in clinics run by
NGOs or private practitioners in five provinces of South
Africa. The clinics provide standardised HIV care and * Correspondence: Katherine.fielding@lshtm.ac.uk
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Aurum Institute. We describe early mortality and loss to
follow-up, and risk factors for mortality in this setting.
Methods
Study design, setting and population
This was a prospective cohort study examining routinely
collected clinic data from an observational cohort of
adult patients to examine risk factors for early mortality.
The clinics contributing data to the study were in urban
and peri-urban sites in five provinces of South Africa
(Gauteng, Limpopo, Free State, Mpumalanga, and North
West). The clinics were either run by a non-government
organisation (NGO), or private practitioners. Training,
clinical and financial support, drug procurement, and
administration and monitoring support were provided
by the Aurum Institute. This programme provided free
antiretroviral treatment to patients who did not have
medical insurance and were unable to pay for their
treatment themselves. The organisation of the pro-
gramme as it was originally developed in an industrial
setting has been described elsewhere [10].
The clinics followed the National South African HIV
treatment guidelines for participants starting ART:
either CD4 <200/μL or classified as in WHO stage 4.
The first line regimen given to the majority of patients
was stavudine, lamivudine, and either nevirapine or efa-
virenz. Patients starting ART attend monthly to collect
medication; they have a clinical review and blood taken
for full blood count and liver function tests at six weeks,
three months and three monthly thereafter; and CD4
c o u n ta n dv i r a ll o a da ts i xw e e k s ,s i xm o n t h sa n ds i x
monthly thereafter.
Patients were included in this analysis if they were
18 years or older when initiating ART treatment, if they
were attending clinics that had over 50 participants in
HIV care in the programme, and if they were ART-
naïve (by self-report) when enrolled into the pro-
gramme. The participants in this cohort all began their
treatment between 1
st February 2005 and 1
st June 2006,
giving them an opportunity to have at least 10 months
follow-up before the cohort was censored on the 31
st
March 2007.
Data sources and follow-up
The data were collected through routine health care ser-
vices. Forms, completed at both scheduled and unsched-
uled visits, included information on CD4 count,
haemoglobin, viral load, height, weight, and previous
treatments. Participants with less than 8 g/mL of hae-
moglobin were classified as severely anaemic, and those
with < 12 (<13 for men) g/mL as anaemic[11]. In this
analysis, patients were followed up from the date of
ART treatment initiation until the date of death, date of
leaving the programme, lost to follow-up or 31
st March
2007, whichever came first. Deregistration forms pro-
vided information on participants leaving the pro-
gramme alive and deaths whilst on treatment. Deaths
were ascertained based on information from relatives or
local hospital services, or by clinic staff attempting to
contact patients who had not attended scheduled fol-
low-up appointments. Records were checked to confirm
that participants without a death or deregistration
recorded were alive and attending the clinic as of 31
st
March 2007. Reasons for leaving the programme, docu-
mented on the deregistration form, were relocated out
of the area, transferred out of the programme or patient
stopped treatment. Patients were defined as lost to fol-
low-up if either the deregistration form documented lost
to follow-up with no supplementary data for the reason
or the most recent clinic visit occurred more than
6 months before 31
st March 2007.
Statistical analysis
Data were analysed using STATA v. 10 (Stata Corpora-
tion, College Station, Texas, USA). CD4 count, viral
load, haemoglobin levels and body mass index (BMI) at
baseline were defined as the results closest to the date
of ART start, restricted to the time interval 90 days
before and 15 days after ART start, with viral load
restricted to within 4 days after ART start, and if more
than one measurement was available, the viral load
before ART start was used.
The cohort was analysed using an intent-to-treat
approach, assuming that once started on ART, patients
remained on ART without interruption [7,12]. Mortality
rates were compared using Poisson regression. Kaplan-
Meier curves were used to summarise survival experi-
ence and Kaplan-Meier probabilities of survival at 3 and
9 months were also calculated for each variable.
Univariable analysis was carried out using the Cox
proportional hazards model with shared frailty to calcu-
late unadjusted hazard ratios for baseline variables.
Shared frailty was used to take into account that indivi-
duals attending the same clinic may be more similar to
each other with respect to outcomes and measures asso-
ciated with outcomes than to those attending other
clinics. Likelihood ratio tests were used to assess depar-
tures from linearity and for linear trend for ordinal vari-
ables. Proportional hazards were assessed by a lexis
expansion at 3 months follow-up time and Schoenfeld
residuals were also examined for departures from the
proportional hazards assumption.
A multivariable model was constructed by retaining
variables that were considered ap r i o r iconfounders and
those that were associated in univariable analysis (p <
0.1 based on likelihood ratio tests). BMI as a baseline
risk factor had more than 20% missing data so a model
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imputed datasets derived [13] and estimates combined
on the basis of Rubin’s Rules [14]. Baseline characteris-
tics of patients who left the programme alive were com-
pared with those who were still in follow-up at the
censoring date for the cohort using the chi-square test
or Wilcoxon rank sum test.
Ethical considerations
This study was approved by the Research Ethics Com-
mittees of the University of KwaZulu-Natal, South
Africa and the London School of Hygiene and Tropical
Medicine, UK. Data were anonymised prior to analysis.
Results
Characteristics of study population
There were 1490 patients reported to be ART-naïve at
the time of ART start between 1
st February 2005 and 1
st
June 2006. Patients were excluded if they had never col-
lected their medication (n = 140), hence there were
1350 included in the analysis (figure 1). These patients
were from 27 clinics (16 in urban and 9 in peri-urban
locations) and were situated in Gauteng (15 clinics),
North West (6), Limpopo (2), Mpumalanga (2) and Free
State (2) provinces.
The patients included in the analysis had a median age
of 35.5 years (interquartile range [IQR] 30.2, 41.9) and
59.8% were female (table 1). At ART start the median
C D 4c o u n tw a s8 3c e l l s / μL, median haemoglobin level
Figure 1 Flow diagram describing antiretroviral therapy cohort inclusion and exclusion criteria and outcome at censoring.
Table 1 Descriptive analysis of all antiretroviral therapy
cohort participants (n = 1350)
Baseline characteristics All patients (n = 1350)
Female 808 (59.8%)
Median age in years (IQR) 35.5 (30.2, 41.9)
CD4 count at baseline n = 1257
Median number of cells per μL (IQR) 83 (27,147)
Count <50 cells per μL 473 (37.6%)
Viral load at baseline n = 1187
Median log10 copies per mL (IQR) 4.92 (4.42, 5.38)
Count >5 log10 copies per mL 533 (44.9%)
Haemoglobin at baseline n = 1206
Median g/mL (IQR) 11.5 (9.9, 13)
Count <8 g/mL (severely anaemic) 105 (8.7%)
Body mass index (BMI) at baseline n = 854
Median kg/m
2 (IQR) 21.4 (18.5, 24.3)
Count <18.5 kg/m
2 (underweight) 207 (24.2%)
Previous tuberculosis diagnosis 314 (23.3%)
Current smoker 177 (13.1%)
Currently drinks alcohol 149 (11%)
Previous tuberculosis preventive therapy 30 (2.2%)
Treatment combination
Stavudine/lamivudine/nevirapine 562 (41.6%)
Stavudine/lamivudine/efavirenz 672 (49.8%)
Zidovudine/lamivudine/efavirenz 55 (4.1%)
Other 61 (4.5%)
Footnote: IQR - Interquartile range;
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copies/mL. The starting regimens included stavudine/
lamivudine/efavirenz for 49.8%, stavudine/lamivudine/
nevirapine for 41.6%, and zidovudine/lamivudine/efavir-
enz for 4.1%. The median BMI was 21.4 (kg/m
2)a n d
8.7% were classified as severely anaemic (<8 g/mL) at
baseline (table 1).
Outcomes and follow-up
The median follow-up time for the 1350 participants in
this cohort was 13.4 months (IQR 10.1, 16.8) with 937
participants alive and in the programme at the censoring
date of 31
st March 2007, and 185 deaths. A total of 228
participants were censored alive before 31
st March 2007;
148 (64.9%) patients were defined as lost to follow-up
and 80 (35.1%) patients left the programme early (30
relocated out of the area, 26 stopped treatment and 24
transferred out of the programme). Those who were
censored alive before 31
st March 2007 compared to
those who were alive at the end of follow-up were more
l i k e l yt ob em a l e( p=0 . 0 1 ,c h i - s q u a r et e s t )a n dt h e i r
median haemoglobin level was 11.4 g/mL compared to
11.8 g/mL (p = 0.03, Wilcoxon rank sum test); there
was no evidence for differences between those who left
the programme and those alive at the end of follow-up
in terms of baseline CD4 count, BMI, and age at ART
start (data not shown).
Mortality rates
There were 185 deaths during follow-up giving an over-
all mortality rate of 13 per 100 person years (pyrs), with
9 4 %a l i v ea t3m o n t h sa n d8 8 %a t9m o n t h s .T h em o r -
tality rate in the first 3 months was 24.5 per 100 pyrs,
decreasing to 13 and 6 per 100 pyrs for 3 - 9 months
and greater than 9 months following the start of ART,
respectively (p < 0.0001). Seventy nine of the deaths
(42.7%) occurred in the first 3 months.
Risk factors for mortality
In univariable analysis using Cox regression with shared
frailty, lower CD4 count, lower haemoglobin, low BMI
and higher viral load, were all found to be associated
with higher mortality (Table 2). The hazard ratios for
participants with CD4 counts between 50 - 99 cells/μL,
100-200 cells/μL and >200 cells/μLc o m p a r e dt ot h o s e
with CD4 count<50 cells/μL were 0.37 [95% confidence
interval (CI) (0.23, 0.58)], 0.28 [95% CI (0.18, 0.42) and
0.21 [95% CI (0.10, 0.45)] respectively. Proportional
hazards were not satisfied for haemoglobin (p = 0.0002).
There was no evidence of associations with hazard of
mortality for ART regimen, previous tuberculosis diag-
nosis, gender, or age (Table 2).
Kaplan-Meier curves show the survival experience for
the whole cohort stratified by baseline CD4 count and
baseline haemoglobin in Figure 2. These show that par-
ticipants with CD4 count <50 cells/μLh a dam u c h
poorer prognosis for survival than participants with
CD4 count ≥ 50 cells/μL and that the survival experi-
ence for those in the highest three categories was very
similar. There was much more of a graded effect for
haemoglobin compared to CD4 count with a clear pat-
tern of an increase in mortality with decreasing haemo-
globin levels.
In multivariable analysis CD4 count and haemoglobin
were independent risk factors for mortality (Table 3).
After adjusting for age, gender, and haemoglobin, indivi-
d u a l sw i t haC D 4c o u n to f< 5 0c e l l s / μLw e r ea tm u c h
higher risk of mortality than those with ≥50 cells/μL, with
an adjusted hazard ratio of 0.4 for CD4 count 50 -
99 cells/μL compared to those with <50 cells/μL. There
was evidence that haemoglobin did not satisfy propor-
tional hazards (p = 0.0003) with a stronger association of
severe anaemia (<8 g/mL) on mortality in the first
3 months on ART (adjusted hazard ratio 4.99) compared
with greater than 3 months on ART (adjusted hazard ratio
1.88; Table 3). Severe anaemia and low CD4 count identify
different patients at higher risk of mortality: amongst
patients with both CD4 count and haemoglobin, of those
severely anaemic 28% (29/105) had CD4 count ≥100/μL
whereas of those with haemoglobin >11.9 g/mL (>12.9 for
men) one quarter (110/435) had CD4 count <50/μL. Viral
load and BMI were not associated with mortality after
controlling for haemoglobin and CD4 count.
There was less than 10% change in the adjusted
hazard ratios for BMI from multiple imputation com-
pared to the adjusted hazard ratios from the reduced
multivariable model with no imputation, after control-
ling for haemoglobin and CD4 count. Evidence for BMI
being associated with mortality was weak (p = 0.11)
which is consistent with the conclusions from the multi-
variable analysis with no imputation.
Discussion and Conclusions
This analysis, based on routinely collected data at clinics
across South Africa, showed that there was high early
mortality on ART with a large proportion (42.7%) of the
deaths occurring in the first three months of treatment,
consistent with other studies from sub-Saharan Africa
[3]. This is most likely attributable to very advanced dis-
ease at treatment start as evidenced by low CD4 count
at baseline, typical of clinics in sub-Saharan Africa
[8,15-17]. High early on-ART mortality rates in
resource-poor settings compared with industrialised
countries are not completely explained by lower CD4
counts and more advanced clinical stage at baseline, but
are probably compounded by co-morbidities, particularly
tuberculosis, that are common in resource-poor settings
[9]. Thus there is a need to identify individuals at high
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concurrent disease within a more intensive case man-
agement programme. This analysis indicates that low
CD4 count and low haemoglobin are important inde-
pendent prognostic factors for mortality in this setting
and either or both could be used to identify those at
highest risk of death.
At three months after ART start, 13% of those with a
b a s e l i n eC D 4c o u n tb e l o w5 0h a dd i e dc o m p a r e dw i t h
3% of those with CD4 count of 50 and above, highlight-
ing the strong association between baseline CD4 count
and early mortality, consistent with other studies
[3,5,7,12,18,19]. Our results are also consistent with
other studies showing that anaemia predicts mortality
Table 2 Unadjusted hazard ratios, 95% confidence intervals and survival probabilities for 3 and 9 months (n = 1350)
Number of patients
(Column %)
Unadjusted hazard
ratio (95% CI)
Likelihood ratio test
p-value
Kaplan-Meier probability of
survival 3 months
9 months
Gender p = 0.49
Male 542 (40.2%) 1 94% 86%
Female 808 (59.8%) 0.9 (0.67, 1.21) 94% 87%
Age group (years) p = 0.14
18 to 29 325 (24%) 1 95% 91%
30 to 34 314 (23.3%) 1.36 (86.7, 2.14) 96% 88%
35 to 39 288 (21.3%) 1.77 (1.14, 2.74) 92% 86%
40 to 49 307 (22.7%) 1.31 (0.83, 2.08) 94% 89%
50 to 70 116 (8.6%) 1.44 (0.79, 2.63) 94% 86%
CD4 count (per μL) (n = 1257) p < 0.0001
0 to 49 473 (37.6%) 1 87% 79%
50 to 99 241 (19.2%) 0.37 (0.23, 0.58) 97% 92%
100 to 200 414 (32.9%) 0.28 (0.18, 0.42) 98% 94%
> 200 129 (10.3%) 0.21 (0.10, 0.45) 97% 95%
Viral load (log10 copies/mL) (n = 1187) p < 0.0001
<4 134 (11.3%) 0.30 (0.15, 0.60) 98% 94%
4 to 5 520 (43.8%) 0.47 (0.34, 0.66) 97% 92%
>5 533 (44.9%) 1 90% 82%
Haemoglobin (g/mL) (n = 1206)* p < 0.0001
<8 105 (8.7%) 3.24 (2.12, 4.94) 79% 66%
8.1 - 9.9 207 (17.2%) 1.94 (1.32, 2.86) 87% 79%
10 - 11.9 (12.9 for men) 453 (37.6%) 1 96% 89%
>11.9 (>12.9 for men) 441 (36.5%) 0.38 (0.24, 0.63) 99% 96%
Body mass index (kg/m
2) (n = 854) p < 0.0001
<18.5 207 (24.2%) 2.05 (1.41, 2.96) 88% 78%
18.5 to 25 471 (55.1%) 1 95% 88%
>25 176 (20.6%) 0.67 (0.38, 1.16) 99% 93%
previous tuberculosis diagnosis p = 0.12
Yes 314 (23.3%) 1.3 (0.94, 1.81) 94% 86%
No 1036 (76.7%) 1 94% 89%
previous tuberculosis preventive therapy
Yes 30 (2.2%) 0.86 (0.31, 2.35) p = 0.77 93% 93%
No 1320 (97.8%) 1 94% 88%
Treatment combination p = 0.41
Stavudine/lamivudine/nevirapine 562 (41.6%) 1 94% 89%
Stavudine/lamivudine/efavirenz 672 (49.8%) 0.91 (0.67, 1.24) 93% 88%
Zidovudine/lamivudine/efavirenz 55 (4.1%) 1.18 (0.57, 2.47) 98% 87%
Other 61 (4.5%) 0.52 (0.21, 1.29) 98% 91%
CI - Confidence Interval.
* Evidence against proportional hazards, p - value for interaction with follow-up time = 0.0002. Unadjusted hazard ratios (95% CI) in the first 3 months of ART for
participants with haemoglobin <8, 8.1-9.9 and >11.9(f)/12.9 (m) g/mL were 3.24 (2.12, 4.94), 1.94 (1.32, 2.86) and 0.38 (0.24, 0.63) respectively comparing to 10-
11.9 (f)/12.9 (m)g/mL, and for greater than 3 months of ART 2.02 (1.09, 3.74), 1.34 (0.77, 2.31), and 0.52 (0.31, 0.89), respectively.
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countries [12,18,20-22] although evidence is limited and
thus this analysis, from a large cohort receiving care at
multiple clinics, adds valuable information to support
this. Anaemia in these settings is associated with condi-
tions such as tuberculosis [Hanifa Y, unpublished data,
personal communication] which may not be clinically
apparent, but could potentially be treated; as well as
other co-morbidities such as malnutrition, gastrointest-
inal Kaposi’s sarcoma etc [19]. Thus those individuals
starting ART with a low haemoglobin in these settings
are in particular need of investigation for, and if neces-
sary treatment of, tuberculosis. More generally haemo-
globin levels could be used by clinics to identify more
promptly participants that are at very high risk of mor-
tality in ART programmes when they start treatment
Figure 2 Kaplan-Meier plots by CD4 count (μL) among 1257 adults starting antiretroviral therapy (top panel) and haemoglobin (g/mL)
levels among 1206 adults starting antiretroviral therapy (bottom panel).
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widely available. There could then be a programme of
intensified case management and monitoring for these
individuals at high risk. This could also involve more
investigation for co-morbidities especially tuberculosis
b u ts h o u l dn o td e l a yt h es t a r to fA R Ta st h e r ei sav e r y
high mortality rate for those waiting to start ART [5].
One in six participants in this cohort left the pro-
gramme during follow-up, and for the majority of these
there was none or only limited information on reasons
for their departure, similar to other ART programmes in
Africa [12,15,23,24]. Although these individuals were
similar to those alive at the end of follow-up in age,
gender, CD4 count, viral load and BMI, the loss to fol-
low-up may also lead to an under-estimate of mortality
rates for this cohort as an unknown number of the
11.0% participants lost to follow-up may have died soon
after leaving the programme. Studies in similar settings
have shown that mortality is often underestimated when
individuals are lost to follow-up and not actively traced
[9,25-27].
A strength of the data presented in this analysis is that
individuals identified in this cohort had definitely started
ART and collected their medication. This helps to
reduce the bias that may occur if individuals who never
started ART were contributing person-years to the
study.
There were missing data for BMI (36.7%) but it was
evaluated in the univariable and multivariable analyses
and conclusions from the multivariable model were sup-
ported by multiple imputation methods. There was also
no information on the cause of death for this cohort
which would have been useful, as what had caused the
early deaths and information regarding the deaths of
those with very low haemoglobin would help to inform
an intensified case management system. However there
is increasing evidence from other studies about the
importance of tuberculosis as an early cause of death
[28,29]
The results from this analysis give evidence that CD4
count and haemoglobin predict early mortality for indi-
viduals on ART in sub-Saharan Africa. Individuals start-
ing ART with either low CD4 count or low
haemoglobin should be targeted for intensified case
management, including investigation for and treatment
of coexistent infections, particularly tuberculosis in set-
tings of high tuberculosis prevalence. In clinics without
access to CD4 counts, haemoglobin may be useful to
identify those at highest risk.
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Table 3 Adjusted hazard ratios for mortality from
multivariate analysis, with 95% confidence intervals
(n = 1195)
Unadjusted HR
1 aHR
2 (95% CI) Likelihood
Ratio test
p-value
Gender 0.41
Male 1 1
Female 0.89 (0.65, 1.23) 0.87 (0.63, 1.2)
Age group
(years)
0.28
18 to 29 1 1
30 to 34 1.43 (0.88, 2.32) 1.37 (0.84, 2.22)
35 to 39 1.85 (1.15, 2.97) 1.67 (1.03, 2.69)
40 to 49 1.27 (0.78, 2.1) 1.25 (0.75, 2.07)
50 to 70 1.44 (0.75, 2.74) 1.57 (0.82, 3.01)
CD4 count
(/μL)
<0.0001
0t o4 9 1 1
50 to 99 0.34 (0.21, 0.55) 0.40 (0.25, 0.64)
100 to 200 0.29 (0.19, 0.45) 0.38 (0.25, 0.58)
> 200 0.22 (0.1, 0.48) 0.34 (0.16, 0.74)
Haemoglobin
(g/mL)
0.0003
3
Time < 3
months
<8 5.35 (2.91, 9.84) 4.99 (2.69, 9.24)
8.1 - 9.9 2.98 (1.67, 5.33) 3.05 (1.71, 5.48)
10 - 11.9 (12.9
for men)
11
>11.9 (>12.9 for
men)
0.10 (0.23, 0.43) 0.12 (0.03, 0.52)
Time ≥ 3
months
<8 2.00 (1.10, 3.70) 1.88 (1.01, 3.49)
8.1 - 9.9 1.27 (0.73, 2.20) 1.33 (0.77, 2.31)
10 - 11.9 (12.9
for men)
11
>11.9 (>12.9 for
men)
0.50 (0.29, 0.86 0.59 (0.34, 1.02)
1 Unadjusted hazard ratio restricted to n = 1195 in model
2aHR (adjusted hazard ratio) adjusted for other variables in the table
3 p-value for interaction with follow-up time.
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